Amgen (AMGN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0311621009

(NASDAQ:AMGN Stock) Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Amgen (AMGN) - Stock Price & Dividends

AMGN Stock Overview

Market Cap in USD 152,040m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1983-06-17

AMGN Stock Ratings

Fundamental 1.59
Dividend 8.31
Growth 5y 6.84
Rel. Performance vs Sector 1.38
Analysts 3.57
Fair Price Total Ret. 287.48
Fair Price DCF 381.47

AMGN Dividends

Yield 12m 3.05%
Yield on Cost 5y 5.37%
Dividends CAGR 5y 7.99%
Payout Consistency 100.0%

AMGN Growth Ratios

Growth 12m 23.00%
Growth Correlation 12m 66%
Growth Correlation 3m 65%
CAGR 5y 11.98%
CAGR / Mean Drawdown 1.51
Sharpe Ratio 12m 0.82
Alpha vs SP500 12m 7.80
Beta vs SP500 5y weekly 0.47
CAPM 6.52%
Average Daily Range 2m 1.99%
Regime Oscillator 5.28
Volatility GJR Garch 1y 29.80%
Price / SMA 50 -3.55%
Price / SMA 200 10.28%
Current Volume 3402.1k
Average Volume 20d 3461.8k
What is the price of AMGN stocks?
As of February 21, 2024, the stock is trading at USD 283.51 with a total of 3,402,098 shares traded.
Over the past week, the price has changed by -1.64%, over one month by -7.17%, over three months by +7.68% and over the past year by +23.00%.
Why is AMGN stock down?
Check with which Index or Commodity AMGN has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return AMGN Return S&P 500
1 Month -7.17% 2.97%
3 Months 7.68% 9.80%
12 Months 23.00% 26.37%
What is the forecast for AMGN stock price target?
According to ValueRays Forecast Model, AMGN Amgen will be worth about 310.5 in February 2025.
Issuer Forecast Upside
Wallstreet Target Price 307.6 8.5%
Analysts Target Price 258.8 -8.7%
ValueRay Target Price 310.5 9.5%